Oak Street Health, Inc. OSH
39.00 0.00 (+0.00%)
At closeMay 1, 2023, 4:00 PM EDT
38.98 Day range 39.00
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) 35.83 -8.1% downside
Now 39.00
- Target (low)
- 21.00
- Target (mean)
- 35.83
- Target (high)
- 64.00
Ratings (-1m) 17 2 buy · 15 hold · 0 sell
- Strong buy1
- Buy1
- Hold15
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 17
- 2 months ago 17
- 3 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.23 | -0.23 – -0.23 | -0.43 | +46.5% | 739.30M | +43.9% | 1 |
| Next quarter | -0.33 | -0.33 – -0.33 | -0.66 | +50.0% | 751.95M | +43.6% | 1 |
| Current year | -1.63 | -1.63 – -1.63 | -2.21 | +26.2% | 3.09B | +42.8% | 1 |
| Next year | -1.49 | -1.49 – -1.49 | -1.63 | +8.6% | 4.32B | +40.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 21, 2023 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Mar 15, 2023 | TD Cowen | Downgrade | Outperform | Market Perform |
| Feb 23, 2023 | JP Morgan | Downgrade | Overweight | Neutral |
| Feb 15, 2023 | Bernstein | Downgrade | Outperform | Market Perform |
| Feb 10, 2023 | Raymond James | Downgrade | Outperform | Market Perform |
| Feb 9, 2023 | Jefferies | Downgrade | Buy | Hold |
| Feb 8, 2023 | Piper Sandler | Downgrade | Overweight | Neutral |
| Feb 8, 2023 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| Feb 8, 2023 | SVB Leerink | Maintained | — | Market Perform |
| Feb 8, 2023 | Stifel | Downgrade | Buy | Hold |
| Jan 12, 2023 | Raymond James | Upgrade | Market Perform | Outperform |
| Jan 10, 2023 | SVB Leerink | Maintained | — | Market Perform |
| Jan 6, 2023 | UBS | Maintained | — | Neutral |
| Nov 21, 2022 | Raymond James | Downgrade | Outperform | Market Perform |
| Nov 14, 2022 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| Nov 10, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Sep 12, 2022 | Goldman Sachs | Downgrade | Buy | Neutral |
| Aug 31, 2022 | Morgan Stanley | Maintained | — | Equal-Weight |
| Aug 31, 2022 | Stifel | Initiated | — | Buy |
| Aug 8, 2022 | Barclays | Maintained | — | Overweight |
| Aug 4, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Aug 3, 2022 | UBS | Maintained | — | Neutral |
| Jun 15, 2022 | B of A Securities | Downgrade | Buy | Underperform |
| Apr 20, 2022 | UBS | Initiated | — | Neutral |
| Apr 19, 2022 | Barclays | Maintained | — | Overweight |
| Mar 30, 2022 | Guggenheim | Initiated | — | Neutral |
| Mar 21, 2022 | Goldman Sachs | Maintained | — | Buy |
| Mar 17, 2022 | Cowen & Co. | Upgrade | Market Perform | Outperform |
| Mar 2, 2022 | Morgan Stanley | Maintained | — | Equal-Weight |
| Mar 2, 2022 | Piper Sandler | Maintained | — | Overweight |